

Table S1. Characteristics of Patients with KAF, AFDAS, and SR in ICH patients.

Characteristics	AFDAS (n=665)	KAF (n=1305)	SR (n=81480)	P (AFDAS vs. KAF)	P*(AFDAS vs. SR)
Age, years	73.3±11.3	73.3±10.5	62.6±12.8	0.5610	<0.0001
Male	410 (61.7)	764 (58.5)	50952 (62.5)	0.1834	0.6409
Hospital grade					
Secondary	241 (36.2)	498 (38.2)	34204 (42.0)	0.4051	0.0028
Tertiary	424 (63.8)	807 (61.8)	47276 (58.0)		
Systolic blood pressure	162.3±30.7	157.3±27.4	164.7±28.2	0.0001	0.0679
GCS at admission	12.0 (7.0-15.0)	13.0 (8.0-15.0)	13.0 (8.0-15.0)	0.1624	0.0017
NIHSS at admission	9.0 (4.0–16.0)	7.0 (3.0–14.5)	6.0 (2.0–12.0)	0.0031	<0.0001
Medical history					
Hypertension	470 (70.7)	1046 (80.2)	58166 (71.4)	<0.0001	0.6866
Diabetes Mellitus	67 (10.1)	215 (16.5)	7621 (9.4)	0.0001	0.5244
Dyslipidemia	24 (3.6)	137 (10.5)	3396 (4.2)	<0.0001	0.4724
Heart failure	4 (0.6)	80 (6.1)	303 (0.4)	<0.0001	0.3338
Myocardial infarction	21 (3.2)	56 (4.3)	662 (0.8)	0.2197	<0.0001
Stroke/TIA	196 (29.5)	607 (46.5)	23115 (28.4)	<0.0001	0.5291
Smoking	208 (31.3)	361 (27.7)	26692 (32.8)	0.0941	0.4177
CHA2DS2-VASC score	3.0 (2.0-4.0)	4.0 (3.0-5.0)	2.0 (1.0-3.0)	<0.0001	<0.0001
Medication history					
Antiplatelet agents	58 (8.7)	296 (22.7)	5378 (6.6)	<0.0001	0.0284
Anticoagulant agents	17 (2.6)	281 (21.5)	1276 (1.6)	<0.0001	0.0410
Antihypertensive agents	309 (46.5)	817 (62.6)	38415 (47.1)	<0.0001	0.7263
Antidiabetic agents	52 (7.8)	158 (12.1)	5582 (6.9)	0.0035	0.3249
Lipid-lowering agents	43 (6.5)	251 (19.2)	4543 (5.6)	<0.0001	0.3191
Fbg, mmol/L	6.0 (5.2-7.5)	6.1 (5.2-7.5)	5.9 (5.1-7.1)	0.9791	<0.0001
LDL-C, mmol/L	2.5 (1.9-3.0)	2.4 (1.8-3.1)	2.6 (2.0-3.2)	0.7635	<0.0001
HbA1c, %	6.0±1.6	6.1±1.7	5.9±1.7	0.0051	0.0054
Creatinine, µmol/L	72.0 (57.0-90.0)	73.0 (60.0-95.0)	67.3 (54.8-84.1)	0.0494	<0.0001
In-hospital complications					
Rebleeding	80 (12.0)	228 (17.5)	6586 (8.1)	0.0017	0.0002
Cerebral infarction	23 (3.5)	50 (3.8)	982 (1.2)	0.6787	<0.0001
Myocardial infarction	10 (1.5)	13 (1.0)	183 (0.2)	0.3213	<0.0001
Seizure	17 (2.6)	33 (2.5)	1123 (1.4)	0.9706	0.0097
Deep venous thrombosis	21 (3.2)	40 (3.1)	1042 (1.3)	0.9105	<0.0001
In-hospital mortality	45 (6.8)	87 (6.7)	1815 (2.2)	0.9329	<0.0001

Data are mean±SD, median (interquartile range), or n (%). AFDAS, atrial fibrillation detected after stroke; Fbg, fasting blood glucose; GCS, Glasgow coma scale; ICH: intracerebral hemorrhage; KAF, known atrial fibrillation; LDL-C, low-density lipoprotein cholesterol; NIHSS, National Institutes of Health Stroke Scale; SR, sinus rhythm; TIA, transient ischemic attack.

Table S2. Characteristics of Patients with KAF, AFDAS, and SR in ischemic stroke patients.

Characteristics	AFDAS (n=18785)	KAF (n=44700)	Synus rhythm (n=755314)	P (AFDAS vs KAF)	P*(AFDAS vs. SR)
Age, years	74.2±10.6	73.9±10.3	65.5±11.9	<0.0001	<0.0001
Male	10100 (53.8)	22502 (50.3)	479724 (63.5)	<0.0001	<0.0001
Hospital grade				<0.0001	<0.0001
Secondary	5505 (29.3)	14023 (31.4)	294679 (39.0)		
Tertiary	13280 (70.7)	30677 (68.6)	460635 (61.0)		
Systolic blood pressure	149.1±24.5	146.5±23.4	150.2±23.0	<0.0001	<0.0001
GCS at admission	12.5 (6.0-15.0)	10.0 (4.0-15.0)	15.0 (10.0-15.0)	0.6658	0.0618
NIHSS at admission	7.0 (3.0-13.0)	6.0 (3.0-14.0)	3.0 (2.0-6.0)	0.0468	<0.0001
Medical history					
Hypertension	10790 (57.4)	28781 (64.4)	488800 (64.7)	<0.0001	<0.0001
Diabetes Mellitus	2623 (14.0)	8498 (19.0)	164278 (21.7)	<0.0001	<0.0001
Dyslipidemia	589 (3.1)	4278 (9.6)	58792 (7.8)	<0.0001	<0.0001
Heart failure	423 (2.3)	3788 (8.5)	4493 (0.6)	<0.0001	<0.0001
Myocardial infarction	442 (2.4)	1845 (4.1)	11746 (1.6)	<0.0001	<0.0001
Stroke/TIA	4397 (23.4)	18949 (42.4)	250515 (33.2)	<0.0001	<0.0001
Smoking	5217 (27.8)	11821 (26.4)	287636 (38.1)	0.0006	<0.0001
CHA2DS2-VASC score	3.0 (2.0-4.0)	4.0 (3.0-5.0)	3.0 (1.0-4.0)	<0.0001	<0.0001
Medication history					
Antiplatelet agents	2745 (14.6)	14305 (32.0)	156364 (20.7)	<0.0001	<0.0001
Anticoagulant agents	685 (3.6)	7533 (16.9)	24939 (3.3)	<0.0001	0.0091
Antihypertensive agents	7579 (40.3)	22609 (50.6)	353724 (46.8)	<0.0001	<0.0001
Antidiabetic agents	1957 (10.4)	6692 (15.0)	128693 (17.0)	<0.0001	<0.0001
Lipid-lowering agents	1817 (9.7)	10416 (23.3)	112748 (14.9)	<0.0001	<0.0001
Fbg, mmol/L	6.5±2.8	6.4±2.7	6.5±3.0	0.0435	<0.0001
LDL-C, mmol/L	2.5 (1.9-3.1)	2.4 (1.8-3.0)	2.7 (2.1-3.4)	<0.0001	<0.0001
HbA1c, %	6.1±1.5	6.2±1.5	6.3±1.8	0.0041	0.9273
Creatinine, µmol/L	74.0 (60.6-90.4)	74.9 (61.0-92.0)	70.0 (58.0-85.0)	<0.0001	<0.0001
In-hospital complications					
Myocardial infarction	182 (1.0)	548 (1.2)	2579 (0.3)	0.0055	<0.0001
Seizure	231 (1.2)	672 (1.5)	3645 (0.5)	0.0079	<0.0001
Deep venous thrombosis	312 (1.7)	983 (2.2)	6150 (0.8)	<0.0001	<0.0001
In-hospital mortality	331 (1.8)	918 (2.1)	2377 (0.3)	0.0157	<0.0001

Data are mean±SD, median (interquartile range), or n (%). AFDAS, atrial fibrillation detected after stroke; Fbg, fasting blood glucose; GCS, Glasgow coma scale; KAF, known atrial fibrillation; LDL-C, low-density lipoprotein cholesterol; NIHSS, National Institutes of Health Stroke Scale; SR, sinus rhythm; TIA, transient ischemic attack.

Table S3. Characteristics of Patients with KAF, AFDAS, and sinus rhythm in SAH patients.

Characteristics	AFDAS (n=76)	KAF (n=108)	SR (n=10730)	P (AFDAS vs KAF)	P*(AFDAS vs. SR)
Age	71.4±10.4	71.0±12.1	59.8±12.9	0.9619	<0.0001
Male	25 (32.9)	35 (32.4)	4387 (40.9)	0.9446	0.1579
Hospital grade					
Secondary	33 (43.4)	40 (37.0)	3379 (31.5)	0.3834	0.0258
Tertiary	43 (56.6)	68 (63.0)	7351 (68.5)		
Systolic blood pressure	154.9±31.3	150.0±27.9	152.6±27.8	0.2180	0.4334
GCS at admission	13.0 (6.0-15.0)	12.0 (7.0-15.0)	15.0 (10.0-15.0)	0.7905	0.0717
Medical history					
Hypertension	53 (69.7)	78 (72.2)	5285 (49.3)	0.7139	0.0004
Diabetes Mellitus	12 (15.8)	20 (18.5)	695 (6.5)	0.6306	0.0011
Dyslipidemia	3 (3.9)	12 (11.1)	325 (3.0)	0.0804	0.6419
Heart failure	1 (1.3)	5 (4.6)	35 (0.3)	0.2127	0.1357
Myocardial infarction	1 (1.3)	7 (6.5)	75 (0.7)	0.0907	0.5214
Stroke/TIA	15 (19.7)	54 (50.0)	2175 (20.3)	<0.0001	0.9082
Smoking	8 (10.5)	24 (22.2)	2328 (21.7)	0.0393	0.0184
CHA2DS2-VASC score	3.0 (2.0-4.0)	4.0 (3.0-5.0)	2.0 (1.0-3.0)	0.0058	<0.0001
Medication history					
Antiplatelet agents	8 (10.5)	28 (25.9)	435 (4.1)	0.0289	0.0078
Anticoagulant agents	6 (7.9)	23 (21.3)	153 (1.4)	0.0140	<0.0001
Antihypertensive agents	37 (48.7)	60 (55.6)	3504 (32.7)	0.3580	0.0030
Antidiabetic agents	6 (7.9)	11 (10.2)	459 (4.3)	0.5973	0.1215
Lipid-lowering agents	4 (5.3)	22 (20.4)	365 (3.4)	0.0038	0.3732
Fbg, mmol/L	7.5±2.9	7.5±3.5	6.9±2.9	0.3052	0.0493
LDL-C, mmol/L	2.5 (2.1-3.2)	2.5 (2.2-3.3)	2.7 (2.1-3.4)	0.4879	0.2704
HbA1c, %	6.3±2.0	6.1±1.8	5.9±1.6	0.3361	0.0389
Creatinine, µmol/L	67.0 (54.1-94.5)	68.7 (56.7-88.1)	60.0 (49.0-76.0)	0.8374	0.0010
In-hospital complications					
Cerebral infarction	2 (2.6)	4 (3.7)	294 (2.7)	0.6868	0.9540
Myocardial infarction	2 (2.6)	4 (3.7)	43 (0.4)	0.6868	0.0026
Seizure	6 (7.9)	6 (5.6)	213 (2.0)	0.5269	0.0003
Deep venous thrombosis	1 (1.3)	7 (6.5)	162 (1.5)	0.0907	0.8900
In-hospital mortality	5 (6.6)	8 (7.4)	315 (2.9)	0.8290	0.0619

Data are mean±SD, median (interquartile range), or n (%). AFDAS, atrial fibrillation detected after stroke; Fbg, fasting blood glucose; GCS, Glasgow coma scale; KAF, known atrial fibrillation; LDL-C, low-density lipoprotein cholesterol; NIHSS, National Institutes of Health Stroke Scale; SAH, subarachnoid hemorrhage; SR, sinus rhythm; TIA, transient ischemic attack.

Table S4. Results of multivariable logistic regression analysis of the risk factors for AFDAS in ICH patients

Variables	OR (95% CI)	P value
age	1.08(1.07,1.09)	<.0001
gender (male vs female)	0.97(0.79,1.21)	0.8156
hospital grade (Secondary vs Tertiary)	0.67(0.54,0.84)	0.0003
Systolic blood pressure	1.00(0.99,1.00)	0.0215
NIHSS score	1.03(1.02,1.04)	<.0001
prior myocardial infarction	1.60(0.78,3.31)	0.2021
prior stroke or TIA	0.97(0.76,1.22)	0.7706
Antiplatelet agents	1.14(0.79,1.65)	0.4875
Fasting blood glucose	1.01(0.98,1.06)	0.4772
LDL-C	0.91(0.83,1.00)	0.0423
Creatinine	1.00(1.00,1.00)	0.3007

AFDAS, atrial fibrillation detected after stroke; ICH, intracerebral haemorrhage; NIHSS, National Institutes of Health Stroke Scale; LDL-C, low-density lipoprotein cholesterol; TIA, transient ischemic attack.

Table S5. Results of multivariable logistic regression analysis of the risk factors for AFDAS in ischemic stroke patients

Variable	OR (95% CI)	P value
age	1.06(1.06,1.06)	<.0001
gender (male vs female)	0.86(0.83,0.90)	<.0001
hospital grade (Secondary vs Tertiary)	0.61(0.59,0.63)	<.0001
NIHSS score	1.09(1.08,1.09)	<.0001
prior hypertension	0.77(0.74,0.80)	<.0001
prior diabetes mellitus	0.64(0.61,0.67)	<.0001
prior heart failure	2.35(2.08,2.66)	<.0001
prior myocardial infarction	1.37(1.22,1.54)	<.0001
prior stroke or TIA	0.60(0.58,0.63)	<.0001
smoking	0.83(0.80,0.87)	<.0001
Antiplatelet agents	0.74(0.70,0.78)	<.0001
Anticoagulation agents	1.58(1.43,1.75)	<.0001
LDL-C	0.80(0.79,0.82)	<.0001
Creatinine	1.00(1.00,1.00)	0.3726

AFDAS, atrial fibrillation detected after stroke; NIHSS, National Institutes of Health Stroke Scale; LDL-C, low-density lipoprotein cholesterol; TIA, transient ischemic attack.

Table S6. Results of multivariable logistic regression analysis of the risk factors for AFDAS in SAH patients

Variable	OR (95% CI)	P value
age	1.07(1.05,1.10)	<.0001
gender (male vs female)	1.28(0.75,2.18)	0.3727
hospital grade (Secondary vs Tertiary)	1.34(0.84,2.12)	0.2175
prior hypertension	1.70(1.02,2.81)	0.0404
prior diabetes mellitus	1.81(0.96,3.41)	0.0669
smoking	0.48(0.21,1.09)	0.078
Creatinine	1.00(1.00,1.00)	0.0009

AFDAS, atrial fibrillation detected after stroke; SAH, subarachnoid haemorrhage;